equiguard

suppresses androgen-dependent LNCaP prostate cancer cell proliferation by targeting cell cycle control via down regulation of the retinoblastoma protein Rb and induction of apoptosis via the release of cytochrome C

Networked: 5 relevant articles (0 outcomes, 2 trials/studies)

Bio-Agent Context: Research Results

Experts

1.	Hsieh, Tze-Chen: 4 articles (01/2008 - 04/2002)
2.	Wu, Joseph M: 4 articles (01/2008 - 04/2002)
3.	Lu, Xiaohua: 3 articles (12/2004 - 04/2002)
4.	Guo, Junqiao: 2 articles (05/2003 - 04/2002)
5.	Chen, Ai-ping: 1 article (09/2008)
6.	Gu, Mei-hua: 1 article (09/2008)
7.	Tian, Shou-fu: 1 article (09/2008)
8.	Xiong, Pei-hua: 1 article (09/2008)
9.	Zhang, Ling: 1 article (09/2008)
10.	Darzynkiewicz, Zbigniew: 1 article (04/2002)

Related Diseases

1.	Neoplasms (Cancer) 12/01/2004 - "In vitro studies in our laboratory have shown that a polyherbal supplement, Equiguard, exhibits anti-tumor activity against hormone dependent LNCaP cells cultured in both androgen-proficient (FBS) and -deficient (CS-FBS) conditions. " 04/01/2002 - "Results show that Equiguard significantly reduced cancer cell growth, induced apoptosis, suppressed expression of the androgen receptor (AR) and lowered intracellular and secreted prostate specific antigen (PSA), and almost completely abolished colony forming abilities of prostate cancer cells. " 05/01/2003 - "Using a panel of CaP cells, we showed that ethanol extracts of Equiguard significantly inhibited cancer cell growth, induced apoptosis, lowered expression of the androgen receptor (AR), decreased intracellular and secreted prostate-specific antigen (PSA) levels and completely abolished the colony forming activities of CaP cells. "
2.	Carcinoma (Carcinomatosis) 04/01/2002 - "Effects of herbal preparation Equiguard on hormone-responsive and hormone-refractory prostate carcinoma cells: mechanistic studies."
3.	Prostatic Neoplasms (Prostate Cancer) 01/01/2008 - "Ethanolic extracts of herbal supplement Equiguard suppress growth and control gene expression in CWR22Rv1 cells representing the transition of prostate cancer from androgen dependence to hormone refractory status." 12/01/2004 - "Clinically relevant anti-prostate cancer effects of Equiguard are vividly illustrated by growth suppression and down regulated expression of prostate specific genes, respectively, androgen receptor (AR) and prostate specific antigen (PSA). " 04/01/2002 - "Results show that Equiguard significantly reduced cancer cell growth, induced apoptosis, suppressed expression of the androgen receptor (AR) and lowered intracellular and secreted prostate specific antigen (PSA), and almost completely abolished colony forming abilities of prostate cancer cells. " 12/01/2004 - "Equiguard suppresses androgen-dependent LNCaP prostate cancer cell proliferation by targeting cell cycle control via down regulation of the retinoblastoma protein Rb and induction of apoptosis via the release of cytochrome c."
4.	Carcinogenesis 04/01/2002 - "The anti-prostatic activities of Equiguard may stem from its complex composition capable of targeting multiple signal transduction/metabolic pathways, to effectively correct, counteract or circumvent the impaired or dysfunctional mechanisms accompanying different stages of prostate carcinogenesis."
5.	Prostatism 09/01/2008 - "Equiguard shows a significant therapeutic effect in treating old patients with SYDS, which could effectively improve the symptoms of prostatism and urosis in patients and is highly safe."

Related Drugs and Biologics

1.	Hormones (Hormone)
2.	Androgens
3.	Plant Preparations (Preparation, Plant)
4.	Prostate-Specific Antigen (Semenogelase)
5.	Androgen Receptors (Androgen Receptor)
6.	Therapeutic Uses
7.	Cytochromes c (Cytochrome c)
8.	Retinoblastoma Protein
9.	Ethanol (Ethyl Alcohol)